Aquestive Therapeutics Faces Class Action Lawsuit
Analysis based on 21 articles · First reported Mar 08, 2026 · Last updated Apr 20, 2026
The class action lawsuit against Aquestive Therapeutics is expected to negatively impact its stock price and investor confidence due to allegations of misleading statements. This event highlights the ongoing scrutiny of pharmaceutical companies regarding drug approval processes and disclosures.
A class action lawsuit has been filed against Aquestive Therapeutics, Inc. by Bronstein, Gewirtz & Grossman, LLC. The lawsuit alleges that Aquestive Therapeutics and certain officers made materially false and misleading statements to investors between June 16, 2025, and January 8, 2026. The core of the complaint centers on the allegedly overstated timeline for the approval and launch of Aquestive's New Drug Application for Anaphylm (dibutepinephrine) sublingual film. Defendants' statements expressing confidence in the NDA submission and assertions of approval by the PDUFA date of January 31, 2026, are claimed to have lacked a reasonable basis. The lawsuit further alleges that the NDA faced significant risks related to human factors concerning the use of the sublingual film, including packaging, administration, use, and labeling, which were concealed or minimized by the defendants. Investors who purchased Aquestive Therapeutics securities during the specified period are encouraged to join the lawsuit.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard